LQ089 · DCL0031

Published LQ089 formulation, expression and tolerability studies

Published LQ089 formulation, expression and tolerability studies

The article and its Supplementary Information report separate IV screening, IV/IM organ studies, storage and acute-toxicity experiments. Their doses, timepoints and cohorts are kept separate.

Research use only. DC Chemicals supplies the lipid only; literature LNP performance depends on the complete formulation and experimental conditions and is not guaranteed.

Wang et al.2024; main17pages and SI77pages · Wang et al., Nature Communications 15, 10804 (2024)

Formulation components and molecular-weight conversion

LQ089 : DSPC : Cholesterol : DMG-PEG2000 = 50 : 10 : 38.5 : 1.5

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

ComponentMW (g/mol)Molar ratioMass at 1 µmol total lipid (mg)
LQ089 · DCL0031694.139500.347069
DSPC · DC57005790.145195960999100.079015
Cholesterol · DCD-041386.6538.50.148860
DMG-PEG2000 · DC4016925071.50.037605

Component mass calculator

Masses are calculated conversions. Editing inputs creates a research scenario; the reported table remains unchanged.

ComponentMW (g/mol)Molar ratiomgMass %
LQ089——
DSPC——
Cholesterol——
DMG-PEG2000——

Masses are calculated conversions. Editing inputs creates a research scenario; the reported table remains unchanged.

Main Methods,p14; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)

Preparation and characterization

SI Table9 reports mean±SD,n=3 for particle characterization. No numerical SD is given for EE or pKa.

Particle size60.900 ± 0.095 nm
PDI0.111 ± 0.004
Encapsulation efficiency95.650%
N/P6:1; Nitrogen/phosphate counting definition not stated
Lipid stockEthanol;individual concentrations not reported
RNA aqueous phaseFirefly luciferase mRNA; Cap1; T7 in vitro transcription. Acidic citrate;strength,pH and RNA concentration not reported
Mixed ethanolic phase12.5 mM total lipid; Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
PNI12 mL/min; aqueous:ethanol3:1 (v/v)
Dialysis / PBS12–24 h; 0.01 M PBS; Amicon-Ultra10 kDa; 0.22 µm

Individual lipid-stock concentrations,RNA input concentration,citrate-buffer strength/pH,injection volume and final administration concentration are not supplied.

Main PDF pp. 14–15; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)

pKa

Main Methods, PDF p. 15; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)

TNS apparent-pKa assay: 6.540

pH2.0–12.0; 2 M NaOH / 2 M HCl
Basal buffer10 mM sodium phosphate +10 mM sodium borate +10 mM sodium citrate +150 mM NaCl
Per well94 µL buffer +4 µL LNP (0.05 mg/mL mRNA, PBS) +2 µL TNS (300 µM,10% DMSO)
Incubation7 min; room temperature; protected from light
Readout / analysisEx 325 nm / Em 435 nm; fluorescence–pH; LogEC50
Calculated from reported aliquots100 µL total; TNS 6 µM; mRNA 2 µg/mL; DMSO 0.2%

Main Methods, PDF p. 15; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)

Cell performance

Rabbit erythrocyte hemolysis is reported. The article/SI does not report a separate LQ089 cellular mRNA-transfection or cell-viability experiment.

Main PDF p. 9; SI Fig.19,p30 · Wang et al., Supplementary Information

Rabbit-RBC hemolysis was reported negative. Mix100µL2%RBC suspension with100µL LNP at50µg/mL mRNA;37°C for3h;supernatant absorbance540nm;n=3,mean±SD. Calculated final conditions:1%RBC and25µg/mL mRNA. Saline and ultrapure water are controls.

SI Fig.19,p30 · Wang et al., Supplementary Information

Animal performance

These results concern complete research LNPs in mice. Injection volumes and final dosing concentrations are not given. A nonsignificant comparison does not establish equivalence or clinical safety.

MainFigs4,6–10; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.4d–e

IV screening: LQ089 exceeded MC3 in the 4–48h expression AUC; its comparison with SM-102 was nonsignificant. LQ089n=3,MC3n=6,SM-102n=5; mean±SD,one-wayANOVA. A numerical fold change is not specified in the text.

ModelFemale BALB/c,6–8weeks
RouteIV
Dose / basis5 µg mRNA / mouse
Timepoints4, 24, 48 h; AUC4–48 h

Resultspp5–6,Fig.4d–e; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.6

IV organ study: the liver was the principal reporter-expression organ at4h. LQ089 showed no significant difference from SM-102. Each group comprised3female+3male BALB/c mice; mean±SD,one-wayANOVA.

ModelBALB/c,3female+3male/group
RouteIV
Dose / basis5 µg mRNA / mouse
Timepoints4 h

Main PDF pp. 7–8,Fig.6a–c; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.7

IM organ study: expression was detected at the injection site and in the liver at4h. This formulation is not described as local-only delivery. Each group comprised3female+3male BALB/c mice; mean±SD,one-wayANOVA.

ModelBALB/c,3female+3male/group
RouteIM
Dose / basis5 µg mRNA / mouse
Timepoints4 h

Main PDF pp. 8–9,Fig.7; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.S13b

Cy5-mRNA distribution: most of the small recovered organ-associated signal was in the liver at4h after IV dosing. This is labeled-RNA distribution,not expressed-protein bioluminescence. SI Fig.13b:n=3,mean±SD.

ModelBALB/c;n=3;cohort sex not separately stated
RouteIV
Dose / basis5 µg Cy5-mRNA / mouse
Timepoints4 h

Main PDF pp. 7–8; Methods, PDF p. 15; SI Fig.13b,p24 · Wang et al., Supplementary Information

Fig.8

LQ089 LNP particle properties remained acceptable during30days at4°C,−20°C and−80°C,while in vivo expression decreased. Freeze/thaw modestly affected expression. Interim sampling is Day14 in text but Day15 on Fig.8axes; cycle count is not stated. These results do not set neat-lipid shelf life.

ModelFemale BALB/c,6–8weeks
RouteIV
Dose / basis5 µg mRNA / mouse
Timepoints4°C / −20°C / −80°C; Day0,14/15,30

Main PDF p. 8; Fig.8a–h,p10 · Wang et al., Nature Communications 15, 10804 (2024)

Figs.9–10,S18

Acute test:20 or100µg mRNA/mouse IV(source:1 or5mg/kg),4female+4male mice per dose,saline placebo,14-day follow-up. A slight ALT rise was reported for LQ089 at100µg; no obvious H&E abnormality was reported. This does not establish clinical safety.

ModelBALB/c,4female+4male/dose
RouteIV
Dose / basis20 / 100 µg mRNA / mouse (1 / 5 mg/kg)
TimepointsDay1,2,3,4,7,9,11,13,14

Main PDF pp. 8–9; Fig.9,p11; Fig.10,p13; Methods, PDF p. 15; SI Figs.16–18,pp27–29 · Wang et al., Nature Communications 15, 10804 (2024)

Literature performance figures

Original mainFigs4,6–10 and SI Figs13,18,19 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. Fig4
Fig4 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · Fig4, PDFp6
Open original figure

Fig4, PDFp6 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. Fig6
Fig6 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · Fig6, PDFp8
Open original figure

Fig6, PDFp8 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. Fig7
Fig7 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · Fig7, PDFp9
Open original figure

Fig7, PDFp9 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. Fig8
Fig8 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · Fig8, PDFp10
Open original figure

Fig8, PDFp10 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. Fig9
Fig9 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · Fig9, PDFp11
Open original figure

Fig9, PDFp11 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. Fig10
Fig10 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · Fig10, PDFp13
Open original figure

Fig10, PDFp13 · Wang et al., Nature Communications 15, 10804 (2024)

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. FigS13
FigS13 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · FigS13, PDFp24
Open original figure

FigS13, PDFp24 · Wang et al., Supplementary Information

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. FigS18
FigS18 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · FigS18, PDFp29
Open original figure

FigS18, PDFp29 · Wang et al., Supplementary Information

Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. FigS19
FigS19 · Original figure;LQ089 is one of the compared formulations. Other lipid groups are retained as source context. · FigS19, PDFp30
Open original figure

FigS19, PDFp30 · Wang et al., Supplementary Information

Cell experiment protocol

Rabbit erythrocyte hemolysis is reported. The article/SI does not report a separate LQ089 cellular mRNA-transfection or cell-viability experiment.

SI Fig.19,p30 · Wang et al., Supplementary Information

Fig.S19

ModelRabbit erythrocytes
RouteIn vitro / ex vivo
Dose / basis100 µL LNP (50 µg/mL mRNA) + 100 µL RBC (2%)
Timepoints37°C; 3 h; A540nm
Replicates / statisticsn=3; mean±SD; saline / ultrapure water
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: Rabbit erythrocytes; Route: In vitro / ex vivo; Dose / basis: 100 µL LNP (50 µg/mL mRNA) + 100 µL RBC (2%)
  5. Mix the stated RBC/LNP aliquots,incubate37°C3h and read supernatantA540. Separation settings are not given. Source formula:hemolysis%=(ODsample−meanODsaline)/meanODultrapurewater×100%.

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

Rabbit-RBC hemolysis was reported negative. Mix100µL2%RBC suspension with100µL LNP at50µg/mL mRNA;37°C for3h;supernatant absorbance540nm;n=3,mean±SD. Calculated final conditions:1%RBC and25µg/mL mRNA. Saline and ultrapure water are controls.

50 µg/mL mRNA · 100 µL LNP

Storage / use

Holding/storage for this specific experiment not separately stated

Main PDF p. 9; SI Fig.19,p30 · Wang et al., Supplementary Information

Animal experiment protocol

Individual lipid-stock concentrations,RNA input concentration,citrate-buffer strength/pH,injection volume and final administration concentration are not supplied.

Main PDF pp. 14–15; Figs4,6–10 · Wang et al., Nature Communications 15, 10804 (2024)

Animal housing / allocation20–26°C,50–60%RH,10h light/14h dark,6mice/cage;food/water ad libitum. Random group assignment; no data excluded. Fudan University IACUC approval. Female screening mice:Vital River.

Main Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.4

ModelFemale BALB/c,6–8weeks
RouteIV
Dose / basis5 µg mRNA / mouse
Timepoints4, 24, 48 h; AUC4–48 h
Replicates / statisticsLQ089n=3; MC3n=6; SM-102n=5; mean±SD; one-wayANOVA
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: Female BALB/c,6–8weeks; Route: IV; Dose / basis: 5 µg mRNA / mouse
  5. At4,24,48h give D-luciferin potassium IP(dose not separately stated for screening),measure whole-body IVIS Spectrum flux and evaluate AUC4–48h; log-transformed flux,one-wayANOVA,Bonferroni,α=.05.

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

5 µg mRNA / mouse; Injection volume and final concentration not reported

5 µg mRNA / mouse

Storage / use

Holding/storage for this specific experiment not separately stated

Resultspp5–6,Fig.4d–e; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.6

ModelBALB/c,3female+3male/group
RouteIV
Dose / basis5 µg mRNA / mouse
Timepoints4 h
Replicates / statisticsn=6 (3F+3M); mean±SD; one-wayANOVA
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: BALB/c,3female+3male/group; Route: IV; Dose / basis: 5 µg mRNA / mouse
  5. At4h give D-luciferin potassium IP3mg/mouse,record whole-body IVIS,then isolate heart,liver,spleen,lungs,kidneys,brain for ex vivo bioluminescence.

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

5 µg mRNA / mouse; Injection volume and final concentration not reported

5 µg mRNA / mouse

Storage / use

Holding/storage for this specific experiment not separately stated

Main PDF pp. 7–8,Fig.6a–c; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.7

ModelBALB/c,3female+3male/group
RouteIM
Dose / basis5 µg mRNA / mouse
Timepoints4 h
Replicates / statisticsn=6 (3F+3M); mean±SD; one-wayANOVA
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: BALB/c,3female+3male/group; Route: IM; Dose / basis: 5 µg mRNA / mouse
  5. At4h give D-luciferin potassium IP3mg/mouse,measure injection-site/whole-body signal and image isolated organs. Muscle site and injection volume are not specified.

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

5 µg mRNA / mouse; Injection volume and final concentration not reported

5 µg mRNA / mouse

Storage / use

Holding/storage for this specific experiment not separately stated

Main PDF pp. 8–9,Fig.7; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.S13b

ModelBALB/c;n=3;cohort sex not separately stated
RouteIV
Dose / basis5 µg Cy5-mRNA / mouse
Timepoints4 h
Replicates / statisticsn=3; mean±SD
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: BALB/c;n=3;cohort sex not separately stated; Route: IV; Dose / basis: 5 µg Cy5-mRNA / mouse
  5. At4h prepare20%organ homogenates inPBS on ice,centrifuge and measure supernatant atEx650/Em670nm. Use organ-matched Cy5-mRNA standard curves and divide recovered amount by5µg. Centrifugation settings and20%basis are not defined.

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

5 µg Cy5-mRNA / mouse; Injection volume and final concentration not reported

5 µg Cy5-mRNA / mouse

Storage / use

Holding/storage for this specific experiment not separately stated

Main PDF pp. 7–8; Methods, PDF p. 15; SI Fig.13b,p24 · Wang et al., Nature Communications 15, 10804 (2024)

Fig.8

ModelFemale BALB/c,6–8weeks
RouteIV
Dose / basis5 µg mRNA / mouse
Timepoints4°C / −20°C / −80°C; Day0,14/15,30
Replicates / statisticsn=3; mean±SD; no significance test
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: Female BALB/c,6–8weeks; Route: IV; Dose / basis: 5 µg mRNA / mouse
  5. Freeze at−20/−80°C and thaw at room temperature;cycle count not stated. Store at4/−20/−80°C,interimDay14(text)/15(axes),terminalDay30. Assess size/PDI/EE,zeta and IV expression(n=3,5µg/mouse,4h).

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

5 µg mRNA / mouse; Injection volume and final concentration not reported

5 µg mRNA / mouse

Storage / use

LQ089 LNP particle properties remained acceptable during30days at4°C,−20°C and−80°C,while in vivo expression decreased. Freeze/thaw modestly affected expression. Interim sampling is Day14 in text but Day15 on Fig.8axes; cycle count is not stated. These results do not set neat-lipid shelf life.

Formulated LQ089 LNPs at4°C,−20°C,−80°C; thaw at room temperature. Interim Day14(text)/Day15(axes); terminal Day30. Cycle count and holding times not given.

Main PDF p. 8; Fig.8a–h,p10 · Wang et al., Nature Communications 15, 10804 (2024)

Figs.9–10,S18

ModelBALB/c,4female+4male/dose
RouteIV
Dose / basis20 / 100 µg mRNA / mouse (1 / 5 mg/kg)
TimepointsDay1,2,3,4,7,9,11,13,14
Replicates / statisticsn=8 (4F+4M); mean±SD; one-wayANOVA
  1. Dissolve individual lipids in ethanol; combine at50:10:38.5:1.5 with12.5mM total lipid in the mixed ethanolic phase.
  2. Prepare mRNA in acidic citrate. Mix at N/P6:1 using PNI microfluidics,reported flow12mL/min and aqueous:ethanol3:1v/v.
  3. Dialyze12–24h into0.01M PBS;concentrate with Amicon-Ultra10kDa MWCO and filter through0.22µm.
  4. Model: BALB/c,4female+4male/dose; Route: IV; Dose / basis: 20 / 100 µg mRNA / mouse (1 / 5 mg/kg)
  5. Monitor weight onDays1,2,3,4,7,9,11,13,14;collect blood/organs onDay14. HEMAVET blood cells and Rayto ALT/creatinine. Fix organs in4%buffered formalin3days,paraffin embed,cut5µm,dewax ethanol/xylene,H&E stain,3DHISTECH scan.

Lipid stock

Ethanol;individual concentrations not reported

Ethanol

RNA aqueous phase

Acidic citrate;strength,pH and RNA concentration not reported

Acidic citrate;strength,pH and RNA concentration not reported

Mixed ethanolic phase

Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.

12.5 mM · Mixed ethanolic phase

Final administration / assay

20 / 100 µg mRNA / mouse (1 / 5 mg/kg); Injection volume and final concentration not reported

20 / 100 µg mRNA / mouse (1 / 5 mg/kg)

Storage / use

Holding/storage for this specific experiment not separately stated

Main PDF pp. 8–9; Fig.9,p11; Fig.10,p13; Methods, PDF p. 15; SI Figs.16–18,pp27–29 · Wang et al., Nature Communications 15, 10804 (2024)

References

Wang W, Chen K, Jiang T, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nature Communications15,10804(2024). · Wang et al., Nature Communications 15, 10804 (2024)

SI§2.4,pp45–51; Table 9, PDF p. 10; Figs13,18,19 · Wang et al., Supplementary Information